Castle Biosciences, Inc. (NASDAQ:CSTL) Insider Derek J. Maetzold Sells 986 Shares

Castle Biosciences, Inc. (NASDAQ:CSTL) insider Derek J. Maetzold sold 986 shares of the company’s stock in a transaction on Friday, October 4th. The stock was sold at an average price of $28.73, for a total transaction of $28,327.78. Following the transaction, the insider now owns 94,622 shares of the company’s stock, valued at $2,718,490.06. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Castle Biosciences Price Performance

Shares of NASDAQ CSTL traded up $0.49 during mid-day trading on Tuesday, reaching $30.01. The company’s stock had a trading volume of 350,853 shares, compared to its average volume of 305,296. The stock has a 50-day moving average of $28.24 and a two-hundred day moving average of $23.96. The stock has a market capitalization of $828.49 million, a P/E ratio of -25.91 and a beta of 1.03. The company has a debt-to-equity ratio of 0.02, a quick ratio of 7.92 and a current ratio of 8.12. Castle Biosciences, Inc. has a 1-year low of $12.07 and a 1-year high of $32.53.

Castle Biosciences (NASDAQ:CSTL) last issued its earnings results on Monday, August 5th. The company reported $0.31 EPS for the quarter, beating analysts’ consensus estimates of ($0.16) by $0.47. The business had revenue of $87.00 million during the quarter, compared to analysts’ expectations of $69.95 million. Castle Biosciences had a negative net margin of 1.08% and a negative return on equity of 0.77%. During the same period in the prior year, the business earned ($0.70) earnings per share. On average, equities research analysts anticipate that Castle Biosciences, Inc. will post -0.58 EPS for the current fiscal year.

Institutional Investors Weigh In On Castle Biosciences

Hedge funds have recently modified their holdings of the company. Vanguard Group Inc. grew its holdings in shares of Castle Biosciences by 2.2% in the first quarter. Vanguard Group Inc. now owns 1,494,176 shares of the company’s stock valued at $33,096,000 after purchasing an additional 32,695 shares during the period. Acadian Asset Management LLC grew its holdings in shares of Castle Biosciences by 130.7% in the first quarter. Acadian Asset Management LLC now owns 210,824 shares of the company’s stock valued at $4,669,000 after purchasing an additional 119,443 shares during the period. Bellevue Group AG grew its holdings in shares of Castle Biosciences by 0.4% in the fourth quarter. Bellevue Group AG now owns 1,232,378 shares of the company’s stock valued at $26,595,000 after purchasing an additional 4,347 shares during the period. Harbor Capital Advisors Inc. grew its holdings in shares of Castle Biosciences by 249.3% in the second quarter. Harbor Capital Advisors Inc. now owns 138,707 shares of the company’s stock valued at $3,020,000 after purchasing an additional 99,001 shares during the period. Finally, Summit Global Investments purchased a new stake in shares of Castle Biosciences in the second quarter valued at about $518,000. Hedge funds and other institutional investors own 92.60% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have weighed in on CSTL. Robert W. Baird upped their price objective on shares of Castle Biosciences from $34.00 to $37.00 and gave the stock an “outperform” rating in a research report on Tuesday, August 6th. Stephens restated an “overweight” rating and set a $37.00 price objective on shares of Castle Biosciences in a research report on Tuesday, August 6th. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Castle Biosciences currently has a consensus rating of “Buy” and a consensus target price of $32.80.

Castle Biosciences Company Profile

Castle Biosciences, Inc, a molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus, uveal melanoma, and mental health conditions. It offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma; DecisionDx-SCC, a proprietary risk stratification GEP test for patients with cutaneous squamous cell carcinoma; MyPath Melanoma, a test used for patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a spatial omics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, or low-grade dysplasia Barrett's esophagus.